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We have constructed a chimeric yellow fever/dengue (YF/DEN) virus, which expresses the premembrane
(prM) and envelope (E) genes from DEN type 2 (DEN-2) virus in a YF virus (YFV-17D) genetic background.
Immunization of BALB/c mice with this chimeric virus induced a CD8 T-cell response specific for the DEN-2
virus prM and E proteins. This response protected YF/DEN virus-immunized mice against lethal dengue
encephalitis. Control mice immunized with the parental YFV-17D were not protected against DEN-2 virus
challenge, indicating that protection was mediated by the DEN-2 virus prM- and E-specific immune responses.
YF/DEN vaccine-primed CD8 T cells expanded and were efficiently recruited into the central nervous systems
of DEN-2 virus challenged mice. At 5 days after challenge, 3 to 4% of CD8 T cells in the spleen were specific
for the prM and E proteins, and 34% of CD8 T cells in the central nervous system recognized these proteins.
Depletion of either CD4 or CD8 T cells, or both, strongly reduced the protective efficacy of the YF/DEN virus,
stressing the key role of the antiviral T-cell response.
Dengue (DEN) virus infection is a global public health prob-
lem, with recurring epidemics in tropical and subtropical re-
gions of Asia, Africa, and the Americas (15). It is estimated
that 100 million cases of dengue fever and 250,000 cases of the
more severe dengue hemorrhagic fever occur annually on a
worldwide basis (24). The incidence of dengue has increased
dramatically during the past 30 years, and a vaccine is urgently
needed.
Dengue virus is a member of the genus Flavivirus of the
family Flaviviridae. This family comprises more than 70 RNA
viruses, many of which are important human pathogens (in
addition to DEN virus, the genus includes such pathogens as
yellow fever virus [YFV], Japanese encephalitis virus [JEV],
and tick-borne encephalitis [TBE] virus). There are four sero-
types of DEN virus, and all four are human pathogens. The
clinical outcomes of DEN virus infection can vary from asymp-
tomatic infection to mild febrile dengue fever to severe and
life-threatening dengue hemorrhagic fever (DHF)-dengue
shock syndrome. The pathogenesis of DHF is not well under-
stood, but a striking feature is that most cases of DHF occur in
individuals who have previously been infected with a heterol-
ogous serotype (8, 15). The concept of antibody-dependent
enhancement of DEN virus infection of monocytes was pro-
posed to explain this condition (8, 11). In support of this
hypothesis, it was shown that DEN viruses replicate to higher
titers in human monocytes in the presence of cross-reactive,
nonneutralizing antibodies in vitro (8, 9, 11, 12). It is believed
that this is due to more efficient infection of monocytes by
virus-antibody complexes binding to the Fcg receptors present
on these cells (8, 11, 12). Although the antibody-dependent
enhancement phenomenon is well documented in vitro, its
importance in vivo remains to be determined. Nevertheless,
the potential role of cross-reactive, nonneutralizing antibodies
in DHF has obvious implications for vaccine design: any effec-
tive dengue vaccine should induce neutralizing antibodies
and/or T-cell immunity against all four serotypes.
The paradigm for flavivirus vaccines is the YFV-17D vaccine
strain (28). The YFV-17D vaccine strain is one of the most
effective and safest vaccines available and induces long-lasting
immunity (1, 21). These properties make the 17D virus very
attractive as a live carrier vaccine. The potential of YFV-17D
as a vaccine vector for other flaviviruses was highlighted by the
observation that the premembrane (prM) and envelope (E)
proteins are interchangeable among different flaviviruses. This
was first demonstrated by Pletnev and coworkers, who showed
that a chimeric virus containing the prM and E genes from
TBE virus (19) or Langat virus (20) and the capsid and non-
structural genes from DEN type 4 (DEN-4) virus grew to high
titers in tissue culture and protected mice against lethal TBE
or Langat virus challenge. More recently, it was shown by
Chambers and colleagues that similar chimeras could be made
based on the YFV-17D genome (4). Chimeric viruses that
carried the prM and E genes from JEV in a YFV-17D genetic
background induced JEV-specific neutralizing antibodies and
provided excellent protection against lethal JEV challenge in
mice (6) and in rhesus monkeys (16, 17). Here, we have used
the same approach to construct chimeric DEN-2/YF viruses.
We found that chimeric viruses expressing the DEN-2 prM and
E genes in a YFV-17D background were immunogenic and
induced solid protection against lethal DEN virus challenge in
BALB/c mice. The chimeric virus induced a DEN-2 prM- and
E-specific CD8 T-cell response and neutralizing antibodies.
We found that the prM- and E-specific CD8 T-cell response
was predominantly directed against an Ld-restricted epitope in
the E protein (25). The population of prM- and E-specific CD8
T cells expanded after the challenge, indicating that vaccine-
primed T cells are efficiently recruited by the challenge virus.
MATERIALS AND METHODS
Mice. Three-week-old female BALB/c mice were purchased from The Jackson
Laboratory (Bar Harbor, Main).
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Peptides. The E protein residues 331 to 339 (SPCKIPFEI; E331) were syn-
thesized at the Biopolymer Synthesis and Analysis Facility at the California
Institute of Technology. The composition of the peptide was ascertained by mass
spectrometry and high-performance liquid chromatography HPLC analysis.
Cells and virus. BHK-21, SW-13, and Vero cells were propagated in minimal
essential medium supplemented with 10% fetal calf serum, 2 mM L-glutamine,
antibiotics, and nonessential amino acids. Virus titers were determined on
BHK-21 cells (YFV-17D and the chimeric YF/DEN virus) or Vero cells (DEN
virus), and virus stocks (YFV-17D and YF/DEN) were grown in SW-13 cells.
A20 cells were maintained in RPMI 1640 supplemented with 10% fetal calf
serum, 2 mM L-glutamine, and antibiotics.
Construction of plasmids. A chimeric YF/DEN-2 virus genome was con-
structed using fusion PCR, following a protocol described by Yao et al. (31). The
proofreading enzyme Pfu polymerase (Stratagene) was used for all amplifica-
tions. The oligonucleotide primer sequences are shown in Table 1. The prM and
E sequences from DEN-2 virus strain PR-159 S1 were amplified from cDNA
clone C8 (7) using primers GB7 and GB8. The GB7 and -8 PCR product was
fused to a 59-terminal YFV-17D fragment amplified from pYF5939IV (23) with
primers GB5 and GB6. The fusion product was amplified with GB5 and GB8 and
cloned into NheI-NsiI-cut pYF5939IV, yielding pYD5939. The chimeric pYFM5.2/
DEN plasmid (pYDM) was made by amplifying the DEN virus E protein cDNA
with primers GB1 and GB2 and amplifying a 39-terminal YFV DNA with primers
GB3 and GB4. The fusion DNA was amplified with primers GB1 and GB4 and
cloned into NsiI-MluI-digested pYFM5.2, yielding pYDM. The sequences of all
PCR-derived DNA fragments were verified by automated sequence analysis.
Transcription and transfection. In vitro ligation of the pYF5939IV and
pYFM5.2 plasmids and the chimeric plasmids (pYD5939 and pYDM) was done
as described previously using NsiI- and AatII-digested DNA fragments (Boehr-
inger Mannheim) (23). Transcription of in vitro-ligated YFV and YF/DEN virus
cDNAs was done according to established protocols. RNA transcripts were
transfected into SW-13 cells using Lipofectin (Gibco), as described previously
(5). Stocks of YFV-17D and YF/DEN virus were obtained by infecting fresh
monolayers of SW-13 cells with the supernatants from transfected cells.
Immunoprecipitation. SW-13 cells were infected with YFV-17D or with the
chimeric YF/DEN virus and were metabolically labeled using Express-35S pro-
tein-labeling mix (NEN) for 2 h at 16 h postinfection. Viral proteins were
immunoprecipitated with hyperimmune sera against YFV-17D (American Type
Culture Collection) or DEN-2 virus (American Type Culture Collection) or with
a polyclonal antiserum against the YFV-17D E protein (29). Cell lysis and
immunoprecipitations were done according to standard protocols. Protein sam-
ples were analyzed on 12% polyacrylamide gels (Bio-Rad).
Immunization and challenge of mice. Three-week-old BALB/c mice were
immunized by subcutaneous (s.c.) injection of 5 3 105 PFU of YFV-17D or
chimeric YF/DEN virus or were mock immunized with phosphate-buffered saline
(PBS). The mice were challenged 2 weeks later by intracerebral (i.c.) injection of
1.5 3 104 PFU (100 50% lethal doses [LD50]) of mouse-adapted, neurovirulent
DEN-2 virus, strain New Guinea C (NGC) (provided by Kenneth Eckels, Walter
Reed Army Institute for Research, Rockville, Md.) (10, 26). The LD50 of the
DEN-2 NGC stock was determined by the method described by Reed and
Muench (22).
Depletion of CD4 and CD8 T cells. To deplete T-cell subsets, immunized mice
were injected intraperitoneally with monoclonal antibodies (MAbs) against CD4
(GK1.5) or CD8 (Lyt 2.43). CD8 T cells were depleted by injecting 0.5 ml (0.5
mg) of Lyt 2.43 MAb 2 days before challenge. CD4 T cells were depleted by
injecting 0.5 ml (0.5 mg) of GK1.5 MAb 2 days before challenge and on the day
of challenge. Depletion of CD4 and/or CD8 T cells was monitored 3 days after
challenge by staining peripheral blood mononuclear cells obtained by retro-
orbital bleeding with fluorescein isothiocyanate-conjugated anti-CD4 (clone
GK1.5) and R-phycoerythrin-conjugated anti-CD8 MAbs (clone 53-6.7) (Pharm-
ingen) and analyzing the cells by flow cytometry. Both regimens resulted in
.99% depletion of the relevant subset.
Isolation of lymphocytes from mouse brain. Isolation of lymphocytes from the
brains of naive or DEN-2 virus-infected mice was done as described previously
(14). Briefly, mouse brains were homogenized using a Tenbroeck homogenizer
and lymphocytes were isolated by centrifugation over a Percoll cushion.
Intracellular cytokine staining. A20 stimulator cells were infected with a
recombinant vaccinia virus expressing the DEN-2 virus prM and E proteins
(provided by Ching-Juh Lai, National Institutes of Health, Bethesda, Md.) (3) or
the NS3 protein (provided by Margo Brinton, Georgia State University) (32) at
a multiplicity of infection of 1 and were used at 8 h postinfection. A20 cells (2 3
105), either vaccinia virus infected, uninfected, or peptide coated (E331-339; 0.1
mg/ml) were incubated with 8 3 105 splenocytes for 6 h in the presence of
brefeldin A (PharMingen). The cells were first surface stained with fluorescein
isothiocyanate-conjugated anti-CD4 (clone GK1.5) and R-phycoerythrin-conju-
gated anti-CD8 (clone 53-6.7) MAbs (PharMingen). Following fixation and per-
meabilization (Cytofix/Cytoperm kit; PharMingen), intracellular cytokine stain-
ing was done using an allophycocyanin-conjugated MAb against gamma
interferon (IFN-g) (clone XMG1.2; PharMingen). Samples were analyzed with a
Becton-Dickinson FACScalibur flow cytometer.
Plaque reduction neutralization assay. Sera from immunized or challenged
mice were obtained by retro-orbital bleeding. After inactivation (30 min; 56°C),
the sera were diluted in minimal essential medium containing 0.25% bovine
serum albumin and guinea pig serum complement and were incubated with 50 to
100 PFU of DEN-2 virus (DEN-2 strain 16681; provided to us by Robert Putnak,
Walter Reed Army Institute for Research) for 30 min at 37°C. Fifty percent
plaque reduction neutralization titers (PRNT50), defined as the reciprocal of the
dilution in which the number of plaques is reduced by 50% compared with the
controls, were determined by plaque assay on Vero cells.
RESULTS
Construction and characterization of chimeric YF/DEN vi-
ruses. A chimeric flavivirus (YF/DEN) was constructed in
which the prM and E genes from YFV-17D were replaced by
their DEN-2 virus counterparts (Fig. 1A). The DEN-2 virus
prM and E genes were derived from the PR-159 S1 candidate
vaccine strain (7). We used the YFV-17D cDNA clones, from
which infectious RNA can be produced (23), to construct the
chimeric YF/DEN virus genome. Full-length YFV-17D and
YF/DEN virus RNAs were transcribed from the in vitro-li-
gated YFV-17D and YF/DEN virus plasmids, respectively, and
were transfected into SW-13 cells. Virus viability was assessed
by plaque titration of progeny virus and by immunofluores-
FIG. 1. (A) Schematic representation of the genome organization of the
chimeric YF/DEN virus. The DEN-2 prM and E genes are indicated by a
cross-hatched bar, and YFV-17D genes are indicated by open bars. (B) Expres-
sion of DEN-2 prM and E genes. SW-13 cells were infected with YFV-17D or
with the chimeric YF/DEN virus and were metabolically labeled at 16 h postin-
fection. The radiolabeled proteins were immunoprecipitated and analyzed on a
12% polyacrylamide gel. Positions of radiolabeled molecular size markers (in
kilodaltons) are on the right.











VOL. 74, 2000 T-CELL RESPONSES AGAINST A CANDIDATE DEN VIRUS VACCINE 8095
cence analysis of the transfected cells (data not shown). On
average, titers of the chimeric YF/DEN virus were threefold
lower than the titer of the parental YF-17D virus (1.1 3 107
versus 3.7 3 107 PFU/ml for YF/DEN virus and YFV-17D,
respectively).
To demonstrate that the DEN-2 virus prM and E genes were
correctly expressed in the YFV-17D background, SW-13 cells
were infected with the chimeric YF/DEN virus or with YFV-
17D and were metabolically labeled for 2 h at 16 h postinfec-
tion. Radiolabeled viral proteins were immunoprecipitated
from infected-cell lysates using antisera against YFV-17D,
DEN-2 virus, and the YFV-17D E protein (Fig. 1B). The
results clearly show that the chimeric YF/DEN virus expresses
the DEN-2 virus prM and E proteins instead of the YFV-17D
prM and E proteins.
Immunogenicity of the chimeric YF/DEN virus. To evaluate
the immunogenicity of the chimeric virus, 3-week-old BALB/c
mice were immunized by s.c. injection of 5 3 105 PFU of
YF/DEN virus. Control mice were immunized with 5 3 105
PFU of YFV-17D or with PBS. We analyzed both T-cell re-
sponses and neutralizing-antibody titers following immuniza-
tion. DEN-2 virus-specific T-cell responses were measured us-
ing an intracellular IFN-g staining assay in which T cells that
produce IFN-g in response to antigen are quantitated by flow
FIG. 2. PrM- and E-specific and E331-epitope-specific CD8 T-cell responses in YF/DEN virus-immunized mice. Mice were immunized by s.c. inoculation with 5 3
105 PFU of YF/DEN virus or YFV-17D or were mock immunized with PBS, and the frequencies of prM- and E-specific CD8 T cells were measured 14 days
postimmunization by intracellular IFN-g staining. The frequencies of specific cells are shown as percentages of total CD8 T cells. The results shown are from individual
mice and differ slightly from the average frequencies presented in the text. vv, vaccinia virus.
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cytometry. In this assay, splenocytes are incubated with antigen
in the presence of the secretion inhibitor brefeldin A to allow
detection of intracellular cytokine. To provide the antigenic
stimulus, we used either BALB/c syngeneic B cells (A20 cells)
infected with a recombinant vaccinia virus expressing the
DEN-2 virus prM and E proteins or A20 cells coated with a
peptide encompassing an Ld-restricted epitope in the E protein
(residues 331 to 339; SPCKIPFEI [25]).
Splenocytes from immunized and control mice were har-
vested 14 days postimmunization and were mixed with recom-
binant vaccinia virus-infected or peptide-coated (E331-339)
A20 cells. As a control, we used uninfected A20 cells. After 6 h
of stimulation, the spleen cells were surface stained with MAbs
against CD4 and CD8 and were then permeabilized to visual-
ize the production of IFN-g in response to antigen. Analysis by
flow cytometry clearly demonstrated that immunization with
the chimeric virus induced a prM- and E-specific CD8 T-cell
response. We found that 1 of 200 CD8 T cells recognized prM-
and E at 14 days postimmunization (3.0 3 104 specific cells per
spleen) (Fig. 2). Of these T cells, approximately 50% were
specific for the E331-339 epitope (Fig. 2). No DEN-2 prM and
E responses were detected in mice immunized with PBS or
with YFV-17D (Fig. 2). To obtain an estimate of the size of the
prM- and E-specific long-term memory pool, we also analyzed
the DEN-2 prM- and E-specific responses at 100 days postin-
fection. We found that prM- and E-specific memory CD8 T
cells were readily detectable at a frequency of 1/700 CD8 T
cells (6.8 3 103 per spleen) 100 days after vaccination (Fig. 3).
Antibody responses were measured by titrating DEN-2-neu-
tralizing antibodies in the serum at 2 and 12 weeks after im-
munization. Neutralizing-antibody titers are expressed as 50%
plaque reduction neutralization titers. Although we could not
detect neutralizing antibodies in any of the immunized mice 2
weeks after immunization, we did observe antibody titers 10
weeks later (PRNT50 5 19). YF/DEN virus-immunized mice
that received a YF/DEN virus booster immunization (5 3 105
PFU, s.c., 12 days after priming) had high titers of neutralizing
antibodies against DEN-2 virus (PRNT50 5 422, 34 days after
the booster immunization). No neutralizing antibodies di-
rected against DEN-2 virus could be detected in PBS- or YFV-
17D-immunized mice at any time.
Challenge of immunized mice. The efficacy of the YF/DEN
vaccine was evaluated by analyzing its capacity to induce pro-
tective immunity against lethal challenge with DEN-2 virus. To
test this, 3-week-old BALB/c mice were immunized with YF/
DEN virus. Control mice were immunized with YFV-17D (5 3
105 PFU, s.c.) or with PBS. YF/DEN virus-immunized and
control mice were challenged by intracerebral (i.c.) injection of
1.5 3 104 PFU (100 LD50) of DEN-2 virus 2 weeks later. As
shown in Fig. 4, immunization with the chimeric YF/DEN virus
induced solid protection against the DEN-2 virus challenge: all
of the mice survived the infection without showing signs of
disease. Survival after DEN-2 virus challenge was not due to
slower kinetics, since all these mice survived for more than 6
months after the challenge. The few surviving mice in the
control groups (Fig. 4) displayed clear signs of malaise, and
their average weights at day 12 postchallenge were lower than
those of the YF/DEN virus-immunized mice (14.2 [n 5 4]
versus 17.8 g [n 5 7]).
The role of vaccine-primed immune responses in mediating
protective immunity was assessed by quantitating T-cell and
antibody responses after the DEN-2 virus challenge. Analysis
of prM- and E-specific T-cell responses after the DEN-2 chal-
lenge revealed a strong, prM- and E-specific CD8 T-cell re-
sponse in the spleens and brains of YF/DEN virus-immunized
FIG. 3. Long-term prM- and E-specific immunity. Mice were immunized by s.c. inoculation with 5 3 105 PFU of YF/DEN virus, and the frequencies of prM- and
E-specific CD8 T cells were measured 100 days postimmunization by intracellular IFN-g staining. The frequencies of specific cells are shown as percentages of total
CD8 T cells. The results shown are from individual mice and differ slightly from the average frequencies presented in the text. vv, vaccinia virus.
FIG. 4. Survival of YF/DEN virus-immunized and control mice after DEN-2
virus challenge.
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and DEN-2 virus-challenged mice. At day 5 after challenge,
prM- and E-specific CD8 T cells (1 of 30 CD8 T cells; 2.2 3 105
per spleen) were readily detected in the spleens of these mice
(Fig. 5). We found no responses after stimulation of the spleen
cells with A20 cells infected with a vaccinia virus recombinant
expressing the DEN-2 virus NS3 protein (Fig. 5). The DEN-2
virus NS3 protein was not encoded by the chimeric YF/DEN
virus used for immunization, and potential NS3-specific re-
sponses after the challenge would therefore represent primary
responses. Thus, the absence of DEN-2 virus NS3-specific re-
sponses after the challenge suggests that the vaccine-primed
(secondary) prM- and E-specific T-cell response was domi-
nant. This experiment (i.e., using the vaccinia virus recombi-
nant expressing NS3) also serves as a control for the prM and
E specificity of the response, since it clearly shows that we do
not observe responses against vaccinia virus proteins.
We found that the prM- and E-specific CD8 T cells effi-
ciently infiltrated the central nervous system (CNS): at day 5
after challenge, one of three CD8 T cells in the brain recog-
nized prM and E (Fig. 6, left panel). PrM- and E-specific
responses in the challenged control mice (i.e., YFV-17D- or
PBS-immunized) were detectable, both in the spleens and in
the brains, but were very weak (Fig. 6, left panel). Our data
also revealed a CD4 T-cell response in the brains of DEN-2
virus-infected mice (Fig. 6, right panel). The A20 stimulator
cells express both major histocompatibility complex class I and
II molecules and could therefore be expected to stimulate both
CD4 and CD8 T cells. Puzzlingly, however, this response was
FIG. 5. PrM- and E-specific CD8 T-cell responses in the spleens of DEN-2 virus-challenged mice. The results shown are from individual mice and differ slightly
from the average frequencies presented in the text. YF/DEN virus-immunized and control mice were challenged by i.c. inoculation with 1.5 3 104 PFU of DEN-2 virus.
The frequencies of prM- and E-specific CD8 T cells in the spleen and in the brain were measured 5 days postchallenge by intracellular IFN-g staining. The frequencies
of specific cells are shown as percentages of total CD8 T cells. vv, vaccinia virus.
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measured after stimulation with both infected and uninfected
A20 cells. There was a small increase after stimulation with the
infected cells (Fig. 6, right panel). The most likely explanation
is that viral antigen is copurified during the isolation of brain
lymphocytes and that this antigen is capable of stimulating the
CD4 T cells. Viral antigen could be endocytosed by the A20
cells (or other antigen-presenting cells) and presented through
the major histocompatibility complex class II pathway. Adding
even more antigen (in the form of vaccinia virus-infected A20
cells) would then result in only a minor increase. Note that
CD4 T-cell responses are measured in all mice, even in YFV-
17D- or PBS-immunized animals, suggesting that these are
primary responses induced by the DEN-2 virus infection in the
CNS.
The neutralizing-antibody titers were similar in the chal-
lenged mice 8 days after infection, regardless of the initial
immunization protocol (PRNT50 5 23, 30, and 33 for PBS-,
YFV-17D, and YF/DEN virus-immunized mice, respectively).
FIG. 6. CD4 and CD8 T-cell responses in the brains of DEN-2 virus-challenged mice. The results shown are from individual mice and differ slightly from the average
frequencies presented in the text. YF/DEN virus-immunized and control mice were challenged by i.c. inoculation of 1.5 3 104 PFU of DEN-2 virus. The frequencies
of responding CD4 and CD8 T cells in the brains of the challenged mice were measured 5 days postchallenge by intracellular IFN-g staining. The frequencies of
responding cells are shown as percentages of total CD4 or CD8 T cells. vv, vaccinia virus.
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Thus, these antibodies appear to be induced by the DEN-2
virus challenge, and the role of the YF/DEN vaccine in induc-
ing these antibodies is unclear. In mice that survived the
DEN-2 virus challenge (after YF/DEN virus immunization),
we found that the neutralizing-antibody titer had increased by
56 days postchallenge (PRNT50 5 77).
Requirements of protective immunity. To address the roles
of CD4 and CD8 T cells in providing protective immunity
against DEN-2 virus challenge, we depleted CD4 and/or CD8
T cells in YF/DEN virus-immunized mice at 12 days after
immunization by intraperitoneal injection of anti-CD4 and/or
anti-CD8 MAbs. The antibody treatments resulted in .99%
depletion of the relevant subset(s) (data not shown). Mice in
which CD4 T cells, CD8 T cells, or both CD4 and CD8 T cells
had been depleted were challenged with DEN-2 virus 2 days
later. As positive and negative controls, we used untreated
YF/DEN virus- and PBS-immunized mice, respectively. As
shown in Fig. 7, in vivo depletion of either T cell subset (or
both) abrogated protection against lethal DEN-2 virus chal-
lenge. The impact of CD4 T-cell depletion appears to be less
than that of depletion of CD8 T cells or depletion of both
subsets. These results demonstrate that both CD4 and CD8 T
cells are required to provide protective immunity against lethal
DEN-2 virus challenge in the CNS.
DISCUSSION
In this study we describe a chimeric YF/DEN virus that
induces both neutralizing antibodies and an antiviral CD8 T-
cell response against the DEN-2 virus prM and E proteins in
BALB/c mice. We found that a single Ld-restricted epitope in
the E protein (residues 331 to 339; SPCKIPFEI) (25) repre-
sents a major target of this CD8 T-cell response. The frequen-
cies of DEN virus-specific T cells that we have measured are
higher than has previously been appreciated. At 5 days post-
challenge, 1 of 30 CD8 T cells in the spleen and 1 of 3 in the
CNS are specific for the viral prM and E proteins, and most of
this response is directed against the E331-339 epitope. Immu-
nization with the chimeric virus provided solid protection
against lethal DEN virus challenge. In contrast, mice immu-
nized with the parental YFV-17D were not protected, demon-
strating that putative flavivirus cross-reactive responses do not
play a significant role in protection. The DEN-2 virus challenge
induced a strong prM- and E-specific CD8 T-cell response only
in the YF/DEN virus-immunized mice, indicating that vaccine-
primed prM and E T cells are recruited efficiently. These prM-
and E-specific CD8 T cells efficiently infiltrated the CNS. This
recruitment of vaccine-primed CD8 T cells after challenge in
YF/DEN virus-immunized mice indicates that these cells may
play a major role in controlling DEN-2 virus infection. The in
vivo depletion experiments confirmed the key role of CD8 T
cells and also demonstrated that the CD4 T-cell response is
important: depletion of either subset reduced protective im-
munity. A requirement for both CD4 and CD8 T cells to
control infections in the CNS has also been shown for JEV (18)
and mouse hepatitis virus (27).
The strategy of creating chimeric flaviviruses has also
yielded promising results in the case of YFV/JEV chimeras (6,
17), DEN-4/TBE virus chimeras (19, 20), and intertypic DEN
virus chimeras (2). In these previous reports, the two param-
eters analyzed were induction of neutralizing antibodies and
protective immunity. In the present study, we not only dem-
onstrate that the chimeric virus provides excellent protective
immunity, but we also show the frequencies and epitope spec-
ificity of the CD8 T cells that are induced by the vaccine.
Immunization with our chimeric YF/DEN virus also induced
neutralizing antibodies, albeit at low titers. DEN-2 virus-spe-
cific neutralizing-antibody titers were below the detection limit
at 2 weeks postimmunization but could be detected at 12 weeks
after immunization or after a booster immunization. Thus, the
chimeric virus was clearly immunogenic in terms of antibody
responses. The weak antibody response after the first immu-
nization is reminiscent of findings reported by Guirakhoo et al.
(6). These authors showed that YFV-neutralizing antibodies
were induced by YFV-17D only when mice had been immu-
nized with low doses of virus. At higher doses (.25,000 PFU),
neutralizing antibody titers decreased dramatically. Since we
used an even higher dose of virus for immunization (5 3 105
PFU), it seems possible that we are observing the same phe-
nomenon. The experience with the YFV-17D vaccine, which
induces strong and long-lasting antibody responses in humans
(21) but weaker responses in mice (6), suggests that our chi-
meric virus may also be more immunogenic in humans than in
mice.
Induction of neutralizing antibodies in humans will be a
highly desirable feature of a DEN virus vaccine, given the
association between cross-reactive, nonneutralizing antibodies
and DHF. To avoid a situation in which the vaccine induces
protective immunity against one DEN virus serotype but
primes the immunized individual for DHF after infection by a
different serotype, it will be important that a candidate DEN
virus vaccine induce neutralizing antibodies and T-cell re-
sponses against all four serotypes simultaneously. Using our
strategy, this can be accomplished by constructing chimeras for
all four serotypes and using these to create a tetravalent vac-
cine. Such a tetravalent vaccine would consist of a cocktail of
the four chimeric viruses. The advantage of our approach,
compared to using a cocktail of attenuated DEN viruses, is that
the genetic backbone (i.e., YFV-17D) will be the same for all
four serotypes. Although the chimeric YF/DEN viruses are
FIG. 7. Survival of DEN-2 virus-challenged mice after immunization with
YF/DEN virus, followed by depletion of CD4 and/or CD8 T cells. The control
groups included PBS- and YF/DEN virus-immunized mice which were not
treated with the depleting antibodies. The surviving mice survived even beyond
the latest time point.
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likely to be attenuated (because the DEN virus- and YFV-
derived proteins are not optimally adapted to each other), the
precise level of attenuation will depend on the source of the
DEN virus prM and E proteins, which will give us a wide
choice in modifying the level of attenuation. The recent dis-
covery that development of DHF is strain specific (30) and may
be correlated with specific amino acid sequences in the E
protein (13) is therefore of critical importance for vaccine
design, since it identifies the sequences that should probably be
avoided.
In summary, both our results and those reported recently for
JEV (6, 16, 17) indicate that the strategy of creating chimeric
flaviviruses opens new avenues for flavivirus vaccine develop-
ment. A particularly promising observation is that the chimeric
YFV/JEV virus appears to be safer than the YFV-17D vaccine
in nonhuman primates (16).
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ADDENDUM IN PROOF
Recently, Guirakhoo and coworkers published an article
(F. Guirakhoo, R. Weltzin, T. J. Chambers, Z.-X. Zhang,
K. Soike, M. Ratterree, J. Arroyo, K. Georgakopoulos, J. Cata-
lan, and T. P. Monath, J. Virol. 74:5477–5485, 2000) that
showed that a chimeric YF/DEN-2 virus is immunogenic and
provides protective immunity in nonhuman primates. We be-
lieve that their data complement our results and that the com-
bined data emphasize the potential of chimeric YF/DEN vi-
ruses as vaccine candidates.
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